• 1
    Bettelli, E., Sullivan, B., Szabo, S. J., Sobel, R. A., Glimcher, L. H. and Kuchroo, V. K., Loss of T-bet, but not STAT1, prevents the development of experimental autoimmune encephalomyelitis. J. Exp. Med. 2004. 200: 7987.
  • 2
    Becher, B., Durell, B. G. and Noelle, R. J., Experimental autoimmune encephalitis and inflammation in the absence of interleukin-12. J. Clin. Invest. 2002. 110: 493497.
  • 3
    Krakowski, M. and Owens, T., Interferon-gamma confers resistance to experimental allergic encephalomyelitis. Eur. J. Immunol. 1996. 26: 16411646.
  • 4
    Lees, J. R., Golumbek, P. T., Sim, J., Dorsey, D. and Russell, J. H., Regional CNS responses to IFN-gamma determine lesion localization patterns during EAE pathogenesis. J. Exp. Med. 2008. 205: 26332642.
  • 5
    Wensky, A. K., Furtado, G. C., Marcondes, M. C., Chen, S., Manfra, D., Lira, S. A., Zagzag, D. and Lafaille, J. J., IFN-gamma determines distinct clinical outcomes in autoimmune encephalomyelitis. J. Immunol. 2005. 174: 14161423.
  • 6
    Langrish, C. L., Chen, Y., Blumenschein, W. M., Mattson, J., Basham, B., Sedgwick, J. D., McClanahan, T. et al., IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J. Exp. Med. 2005. 201: 233240.
  • 7
    Cua, D. J., Sherlock, J., Chen, Y., Murphy, C. A., Joyce, B., Seymour, B., Lucian, L. et al., Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain. Nature 2003. 421: 744748.
  • 8
    Durelli, L., Conti, L., Clerico, M., Boselli, D., Contessa, G., Ripellino, P., Ferrero, B. et al., T-helper 17 cells expand in multiple sclerosis and are inhibited by interferon-beta. Ann. Neurol. 2009. 65: 499509.
  • 9
    Matusevicius, D., Kivisakk, P., He, B., Kostulas, N., Ozenci, V., Fredrikson, S. and Link, H., Interleukin-17 mRNA expression in blood and CSF mononuclear cells is augmented in multiple sclerosis. Mult. Scler. 1999. 5: 101104.
  • 10
    Hofstetter, H. H., Ibrahim, S. M., Koczan, D., Kruse, N., Weishaupt, A., Toyka, K. V. and Gold, R., Therapeutic efficacy of IL-17 neutralization in murine experimental autoimmune encephalomyelitis. Cell. Immunol. 2005. 237: 123130.
  • 11
    Komiyama, Y., Nakae, S., Matsuki, T., Nambu, A., Ishigame, H., Kakuta, S., Sudo, K. and Iwakura, Y., IL-17 plays an important role in the development of experimental autoimmune encephalomyelitis. J. Immunol. 2006. 177: 566573.
  • 12
    Haak, S., Croxford, A. L., Kreymborg, K., Heppner, F. L., Pouly, S., Becher, B. and Waisman, A., IL-17A and IL-17F do not contribute vitally to autoimmune neuro-inflammation in mice. J. Clin. Invest. 2009. 119: 6169.
  • 13
    Harrington, L. E., Hatton, R. D., Mangan, P. R., Turner, H., Murphy, T. L., Murphy, K. M. and Weaver, C. T., Interleukin 17-producing CD4+effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat. Immunol. 2005. 6: 11231132.
  • 14
    Lovett-Racke, A. E., Rocchini, A. E., Choy, J., Northrop, S. C., Hussain, R. Z., Ratts, R. B., Sikder, D. and Racke, M. K., Silencing T-bet defines a critical role in the differentiation of autoreactive T lymphocytes. Immunity 2004. 21: 719731.
  • 15
    O'Connor, R. A., Prendergast, C. T., Sabatos, C. A., Lau, C. W., Leech, M. D., Wraith, D. C. and Anderton, S. M., Cutting edge: Th1 cells facilitate the entry of Th17 cells to the central nervous system during experimental autoimmune encephalomyelitis. J. Immunol. 2008. 181: 37503754.
  • 16
    Bending, D., De La Pena, H., Veldhoen, M., Phillips, J. M., Uyttenhove, C., Stockinger, B. and Cooke, A., Highly purified Th17 cells from BDC2.5NOD mice convert into Th1-like cells in NOD/SCID recipient mice. J. Clin. Invest. 2009. 119: 565572.
  • 17
    Stromnes, I. M., Cerretti, L. M., Liggitt, D., Harris, R. A. and Goverman, J. M., Differential regulation of central nervous system autoimmunity by T(H)1 and T(H)17 cells. Nat. Med. 2008. 14: 337342.
  • 18
    Viville, S., Neefjes, J., Lotteau, V., Dierich, A., Lemeur, M., Ploegh, H., Benoist, C. and Mathis, D., Mice lacking the MHC class II-associated invariant chain. Cell 1993. 72: 635648.
  • 19
    Bikoff, E. K., Huang, L. Y., Episkopou, V., van Meerwijk, J., Germain, R. N. and Robertson, E. J., Defective major histocompatibility complex class II assembly, transport, peptide acquisition, and CD4+T cell selection in mice lacking invariant chain expression. J. Exp. Med. 1993. 177: 16991712.
  • 20
    Chiu, B. C., Freeman, C. M., Stolberg, V. R., Komuniecki, E., Lincoln, P. M., Kunkel, S. L. and Chensue, S. W., Cytokine-chemokine networks in experimental mycobacterial and schistosomal pulmonary granuloma formation. Am. J. Respir. Cell. Mol. Biol. 2003. 29: 106116.
  • 21
    Badovinac, V., Mostarica-Stojkovic, M., Dinarello, C. A. and Stosic-Grujicic, S., Interleukin-1 receptor antagonist suppresses experimental autoimmune encephalomyelitis (EAE) in rats by influencing the activation and proliferation of encephalitogenic cells. J. Neuroimmunol. 1998. 85: 8795.
  • 22
    Anthony, D., Dempster, R., Fearn, S., Clements, J., Wells, G., Perry, V. H. and Walker, K., CXC chemokines generate age-related increases in neutrophil-mediated brain inflammation and blood-brain barrier breakdown. Curr. Biol. 1998. 8: 923926.
  • 23
    Jager, A., Dardalhon, V., Sobel, R. A., Bettelli, E. and Kuchroo, V. K., Th1, Th17, and Th9 effector cells induce experimental autoimmune encephalomyelitis with different pathological phenotypes. J. Immunol. 2009. 183: 71697177.
  • 24
    King, I. L., Dickendesher, T. L. and Segal, B. M., Circulating Ly-6C+myeloid precursors migrate to the CNS and play a pathogenic role during autoimmune demyelinating disease. Blood 2009. 113: 31903197.
  • 25
    McQualter, J. L., Darwiche, R., Ewing, C., Onuki, M., Kay, T. W., Hamilton, J. A., Reid, H. H. and Bernard, C. C., Granulocyte macrophage colony-stimulating factor: a new putative therapeutic target in multiple sclerosis. J. Exp. Med. 2001. 194: 873882.
  • 26
    Ponomarev, E. D., Shriver, L. P., Maresz, K., Pedras-Vasconcelos, J., Verthelyi, D. and Dittel, B. N., GM-CSF production by autoreactive T cells is required for the activation of microglial cells and the onset of experimental autoimmune encephalomyelitis. J. Immunol. 2007. 178: 3948.
  • 27
    Sonderegger, I., Iezzi, G., Maier, R., Schmitz, N., Kurrer, M. and Kopf, M., GM-CSF mediates autoimmunity by enhancing IL-6-dependent Th17 cell development and survival. J. Exp. Med. 2008. 205: 22812294.
  • 28
    Kroenke, M. A., Carlson, T. J., Andjelkovic, A. V. and Segal, B. M., IL-12- and IL-23-modulated T cells induce distinct types of EAE based on histology, CNS chemokine profile, and response to cytokine inhibition. J. Exp. Med. 2008. 205: 15351541.
  • 29
    Carlson, T., Kroenke, M., Rao, P., Lane, T. E. and Segal, B., The Th17-ELR+CXC chemokine pathway is essential for the development of central nervous system autoimmune disease. J. Exp. Med. 2008. 205: 811823.
  • 30
    Zhou, J., Stohlman, S. A., Hinton, D. R. and Marten, N. W., Neutrophils promote mononuclear cell infiltration during viral-induced encephalitis. J. Immunol. 2003. 170: 33313336.
  • 31
    Anthony, D. C., Bolton, S. J., Fearn, S. and Perry, V. H., Age-related effects of interleukin-1 beta on polymorphonuclear neutrophil-dependent increases in blood-brain barrier permeability in rats. Brain 1997. 120: 435444.
  • 32
    Tigno-Aranjuez, J. T., Jaini, R., Tuohy, V. K., Lehmann, P. V. and Tary-Lehmann, M., Encephalitogenicity of complete Freund's adjuvant relative to CpG is linked to induction of Th17 cells. J. Immunol. 2009. 183: 56545661.
  • 33
    Izcue, A., Hue, S., Buonocore, S., Arancibia-Carcamo, C. V., Ahern, P. P., Iwakura, Y., Maloy, K. J. and Powrie, F., Interleukin-23 restrains regulatory T cell activity to drive T cell-dependent colitis. Immunity 2008. 28: 559570.
  • 34
    Niedbala, W., Wei, X. Q., Cai, B., Hueber, A. J., Leung, B. P., McInnes, I. B. and Liew, F. Y., IL-35 is a novel cytokine with therapeutic effects against collagen-induced arthritis through the expansion of regulatory T cells and suppression of Th17 cells. Eur. J. Immunol. 2007. 37: 30213029.
  • 35
    Lucchinetti, C., Bruck, W., Parisi, J., Scheithauer, B., Rodriguez, M. and Lassmann, H., Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann. Neurol. 2000. 47: 707717.